Staphylococcal protein A (SpA) is an important virulence factor from Staphylococcus aureus responsible for the bacterium's evasion of the host immune system. SpA includes five small threehelix-bundle domains that can each bind with high affinity to many host proteins such as antibodies. The interaction between a SpA domain and the F c fragment of IgG was partially elucidated previously in the crystal structure 1FC2. Although informative, the previous structure was not properly folded and left many substantial questions unanswered, such as a detailed description of the tertiary structure of SpA domains in complex with F c and the structural changes that take place upon binding. Here we report the 2.3-Å structure of a fully folded SpA domain in complex with F c . Our structure indicates that there are extensive structural rearrangements necessary for binding F c , including a general reduction in SpA conformational heterogeneity, freezing out of polyrotameric interfacial residues, and displacement of a SpA side chain by an F c side chain in a molecular-recognition pocket. Such a loss of conformational heterogeneity upon formation of the protein-protein interface may occur when SpA binds its multiple binding partners. Suppression of conformational heterogeneity may be an important structural paradigm in functionally plastic proteins.
Staphylococcus aureus virulence | conformational heterogeneity | staphylococcal protein A | X-ray crystallography | immunoglobulin Fc binding T he Gram-positive bacterium Staphylococcus aureus is commonly found on the skin and in the respiratory tract and can cause a variety of health complications ranging from skin lesions and boils to more serious infections such as sepsis and endocarditis (2, 3) . Staphylococcal protein A (SpA) is an important virulence factor found on the surface of S. aureus cells. This 42-kDa protein has two functional halves: the N-terminal half, which consists of five protein-binding domains (E-D-A-B-C) with high sequence identity that are each able to bind to many different partner proteins, and the C-terminal half, which is responsible for anchoring the protein in the cell wall.
SpA has a wide range of functions that require binding to many target proteins in the host during infection (Fig. 1 ). One such target is tumor necrosis factor receptor 1 (TNFR1), which binds to residues on helix 1 (F5, F13, Y14, and L17) and helix 2 (I31 and K35) on all five SpA protein-binding domains and competes for antibody binding (4) . SpA binding mimics TNF-α activation of airway cells, leading to inflammation (5) . SpA also binds the A1 domain of the hemostasis protein von Willebrand factor (vWf) with 15-nM affinity (6) using residues on helix 1 (Q10, F13, Y14, and L17) and helix 2 (N28, I31, and K35), which allows S. aureus to adhere to surfaces (7) .
In addition to its roles in inflammation and platelet adhesion, SpA also assists S. aureus's adept evasion of the immune system by binding host IgG and IgM antibodies. Each SpA domain can bind both F c and F ab fragments, with SpA's affinity for F c (K D 10-30 nM) ∼30-fold tighter than that for F ab (8, 9) . This unusual mode of antibody binding inhibits binding of the F c subunit to the host phagocyte F c receptor, thereby protecting the bacterial cell from phagocytosis (10) .
The SpA domain-F c interaction was partially elucidated previously in the crystal structure 1FC2 to 2.8-Å resolution (11) . In this structure, the SpA B domain (SpA B ) binds to the hinge region between the CH2 and CH3 domains of F c . The SpA side of the interface is the helix 1/2 face of SpA B , which makes many contacts with the antibody at S254, Q311, L432, and N434. The residues on the SpA-domain side that contact F c reside on helix 1 (F5, Q9, Q10, N11, F13, Y14, and L17) and helix 2 (N28, I31, Q32, and K35) (11) . The 1FC2 structure guided subsequent mutagenesis experiments from other groups. A two-helix derivative of an engineered SpA B with selected substitutions bound to F c with comparable affinity to the wild-type domain (12) . In another study, mutation of other key residues, including the Q9K/Q10K/ D36A/D37A variant of SpA B , greatly reduced the affinity of SpA B for F c (13) . SpA domains also bind the F ab fragments of antibodies, albeit also not at the canonical antigen-binding interface. A crystal structure of the SpA D domain (SpA D ) in complex with F ab from IgM at 2.7-Å resolution (PDB ID code 1DEE) showed that a VH region forms the SpA interface (10) . On the F ab side, this interface is formed by framework β-strands and interstrand loops that are distant from the antigen-combining site. The interaction between SpA domains and F ab is thought to contribute to selection of VH3-encoded B-cell antigen receptors (14) , as well as suppression and deletion of B lymphocytes (15) as a consequence of S. aureus infection. SpA D residues involved in binding F ab reside on helix 2 (Q26, G29, F30, Q32, S33, and D36) and helix 3 (N43, E47, and L51) (10) . These residues are distinct from the residues bound to F c in the 1FC2 structure.
Significance
The emergence of antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, is an increasing threat to human health. S. aureus infections cause a variety of health complications, ranging from skin lesions to life-threatening infections. Staphylococcal protein A (SpA) is the major cell-surface protein and a multitarget virulence factor. The design of SpAtargeted therapeutics requires a molecular description of its interactions with host proteins. Here we report the crystal structure of a complete SpA domain in complex with an F c fragment of human IgG. Our structure reveals changes in SpA when it binds to F c , including a significant reduction in conformational heterogeneity as well as displacement of a SpA side chain by an F c side chain in a molecular-recognition pocket. We previously reported the ultra-high-resolution crystal structures of SpA C and SpA B-B (two SpA B domains connected by the conserved linker) (16) . These structures exhibited extensive conformational heterogeneity, with many concerted conformational changes both at the residue level and at the tertiary-structure level. Over 60% of residues in each structure contained alternative conformations of either backbone or side chain. In addition, helix 1 assumed many different poses, both within each structure as alternative conformations and among structures, both ours and those previously reported. If this enhanced heterogeneity of helix 1 is also present in SpA domains in solution, it may be responsible for the functional plasticity at the helix 1/2 interface, which binds many different partner proteins.
As a very early structure of an antibody molecule in complex with another protein, the original 1FC2 F c -SpA B structure was seminal (11) . However, this work left many substantial structural and functional questions unanswered. In addition, helix 3 of the three-helix-bundle SpA B was folded irregularly in the 1FC2 structure. This observation initially led investigators to speculate that unfolding of one of the three helices was concomitant with binding. Subsequent NMR-detected amide exchange studies (17) (18) (19) showed that all three helices are fully formed when the SpA domain is bound to F c in solution, indicating that the absence of a folded helix 3 in the 1FC2 structure is likely a crystallization artifact. Structure determination of the complex by NMR has not been possible to date. Thus, a detailed description of the changes in conformational heterogeneity in the SpA domain that take place upon binding F c has remained unresolved before the structure we report here. Does the ability of SpA domains to bind multiple proteins at the same site stem from a capacity to suppress conformational heterogeneity at a partner-specific complementary interface? What role does displacement of intramolecular side chains play upon binding of F c ? These questions were not addressed by either the previous apo NMR structures or the 1FC2 crystal structure. The structure we report here provides some key answers.
To investigate the detailed conformational state of SpA domains when bound to F c , we solved the structure of SpA C in complex with F c at 2.3-Å resolution (Fig. 1) . The structure shows that both interfacial and noninterfacial SpA C residues have decreased conformational heterogeneity compared with the apo structure. In addition, we have successfully decreased affinity of SpA C for F c by prefilling a molecular-recognition pocket with a Q9W substitution. This hydrophobic pocket is filled intramolecularly by the F5 ring in the WT apo structure, but this side chain is displaced by I253 of F c in the complex. We have solved the crystal structures both of apo SpA C Q9W and of SpA C Q9W bound to F c . Our results suggest that a small-molecule drug bound to this pocket could hinder antibody binding in a similar way.
Results and Discussion
Overview of the F c -SpA C Complex Structure. To elucidate the atomiclevel details of SpA C when bound to the F c fragment of IgG, we crystallized both proteins in complex with one another. An intact IgG in vivo includes two chains of F c linked by two disulfide bonds at the C-terminal end of the domain, which together form a dimeric IgG fold at the N-terminal end. To facilitate correct disulfide formation, we truncated the protein before the two C-terminal cysteines to produce an unlinked single F c chain (hereafter referred to as "F c monomer").
Tetragonal bipyramidal crystals of the F c -SpA C complex grew in the space group C2 (Experimental Procedures). Diffraction data were collected to 2.3-Å resolution at cryogenic temperatures and solved by molecular replacement using SpA C from PDB ID codes 4NPD (16) and 1FC2 (11) as the search models (Table S1 ). The asymmetric unit contains three molecules of SpA C (chains A-C) complexed with three molecules of F c monomer (chains D-F). The three F c monomers have a mean pairwise rmsd value of 0.26 Å, as do the three SpA C molecules. Despite being purified as a single chain, each F c monomer in the structure forms a dimer with another F c monomer to form the typical IgG fold. Fig. 2 depicts an F c dimer in complex with four SpA C molecules. The F c loops distant from the IgG fold are conformationally diverse and have poor electron density, and no density was observed for the C-terminal F c 6×His tag. There are several similarities between the 1FC2 structure and the one reported here. The three SpA C molecules in our ig. 2. New F c -SpA C cocrystal structure at 2.3 Å. Despite missing the two disulfide-forming C-terminal cysteine residues, the F c molecules (blue) form a dimer with the canonical IgG fold. Two SpA C molecules (light cyan; Left) use the helix 1/2 interface (dots) described previously (11) . The new previously unobserved interface is formed with the helix 2/3 face of two other SpA C molecules (turquoise), shown in ribbon and cartoon form (Right). structure bind to F c at the previously described location (11) , at the hinge between the CH2 and CH3 domains of F c (Fig. S1A) . Also, the global F c fold matches that seen in 1FC2. The CH2 and CH3 domains each superimpose well, with mean rmsd values of 0.48 and 0.43 Å, respectively. However, the mean rmsd value for the entire F c monomer rises to 0.64 Å, presumably because the angle between the CH2 and CH3 domains is larger in 1FC2 than in the current structure. In addition, the individual C-terminal loops in the 1FC2 structure also adopt slightly different conformations from in the current structure, and any differences in loop conformation are likely due to crystal packing. These loops have not been implicated in binding to SpA and, therefore, do not affect analysis of the complex.
Although the F c molecules from the new complex and from 1FC2 adopt very similar conformations, the biggest difference between the two structures is on the SpA-domain side. The F c interface, formed from helix 1 and helix 2 of SpA B , is properly folded in 1FC2. However, residues 42-47 were folded irregularly in the old structure and, therefore, not modeled as a helix, and residues 48-58 were not modeled at all (11) . Consequently, no information is available about the true structure or conformational heterogeneity of one-third of the SpA domain in 1FC2. In the new structure, all three helices are properly folded. Another difference between the current complex structure and 1FC2 is the SpA-domain sequence. The current structure includes a SpA C domain, whereas 1FC2 has SpA B . However, only five residues differ between the two domains ( Fig. S1B ). N/T23, A/K42, and L/I44 are not involved in an interface, and Q/V40 and N/E43 are not involved in the primary (helix 1/2) interface.
Residues at the Helix 1/2 Interface Undergo Concerted Conformational
Changes upon F c Binding. Previously, we showed that SpA domains are conformationally heterogeneous throughout, both at the individual-residue level and at the tertiary-structure level (16) . The interfacial residues (Q10, F13, Y14, L17, H18, and I31) for the F c -binding site are particularly heterogeneous, with multiple identifiable backbone and side-chain conformations in the electron density. In the current structure, electron density for the helix 1/2 interfacial residues is clearly represented by a single model (Fig.  3A) where each residue has only one side-chain rotamer at both 1σ (purple mesh) and 0.3σ (gray surface) electron density. Therefore, the interacting residues on helix 1/2 apparently adopt a single conformation to form an interface that is compatible with the F c molecule.
Previous work comparing the apo SpA C structure with the 1FC2 structure suggested that concerted rotamer changes were needed for compatible F c binding. To update this comparison with our new structure, we superimposed the helix 1/2 interface of our F c -SpA C complex structure onto the 4NPD SpA C (orange) and 4NPF SpA B-B chain X (green) structures (Fig. 3B ). Whereas the majority of residues in SpA C remain conformationally diverse outside of the interface, each of the six helix 1/2 interfacial residues adopts a single rotamer in the complex. The most drastic change is at Y14, whose ring swings 180°away from the tyrosine ring in apo SpA C . The apo SpA B-B structure captures both of these rotamers (16) . The new SpA C -F c complex structure at 2.3 Å has poorer resolution than the apo SpA C structure at 0.9 Å, making it difficult to compare the conformational heterogeneity between the two structures by simply counting the number of alternative conformations. At high resolution, the maximum distance between equivalent atoms of alternative conformations is a convenient measurement of the conformational heterogeneity. However, at poorer resolutions, where discrete alternative conformations may not always be visible, another metric must be used to quantify the conformational heterogeneity. The electron-density map value is one such metric. By comparing the ratio of the backbone and side-chain electron-density map values, hereafter referred to as the "ρ ratio" (R ρ ), one can compare the conformational heterogeneity between structures of varying resolutions.
To quantify the conformational heterogeneity for all residues except alanine and glycine, which have no side-chain rotamers, we calculated R ρ = (ρ cɑ − ρ cɣ )/ρ cɑ , where ρ CX is the value of the 2F o − F c map for carbon atom X in electrons per Å 3 using phenix.map_value_at_point with the default resolution_factor (20) . For residues with more than one C ɣ atom, the average C ɣ map value was used. Because backbone contour levels are usually greater than or equal to the side-chain levels, R ρ ranges from 0 (no difference between backbone and side chain) to 1 (no detectable side-chain density). R ρ s for chain A of the complex and for the SpA C apo structure are listed in Table S2 and depicted as putty diagrams in Fig. 3 C and D, respectively, where the relative diameter of the putty represents the ρ ratio. Side chains that form the helix 1/2 interface, shown in blue, are conformationally heterogeneous in the apo structure, but this rotameric conformational heterogeneity is frozen out in the complex structure, as indicated by a thin putty diameter. ) were recorded using standard methods (Experimental Procedures). Stereo-specific assignments were determined for Leu and Val residues based on the assumption that the crystal structures and solution structures share the same predominant rotamer conformation. In addition, the chemical shifts of δ 1 carbons of isoleucine residues and the differences in chemical shifts for the δ 1 and δ 2 carbons of leucine residues were used to determine the extent of averaging due to rotation around the χ 2 angle. These data are summarized in Table S3 for the 14 residues that yielded observations. Of the 14 residues, 8 show at least two alternate conformations in the apo SpA C crystal structure and have dynamics in χ 1 or χ 2 by NMR. Two of these, L17 and I31, are found at the F c interface and lose their conformational heterogeneity in the crystal structure of the complex, as judged by the lack of alternate side-chain conformations detected by qFit (24) and by their low ρ ratios (0.24 and 0.13, respectively). Unfortunately, the 4 remaining interfacial residues were not among the 14 side chains whose dynamics were observable in our NMR experiments, so the loss in heterogeneity observed in the crystal structures for these residues has not been confirmed by NMR. Two of the 14 residues observed by NMR (L22 and V40) show no sidechain dynamics in solution or in crystals. Of the remaining 4 residues a missing assignment precludes comparison for K49, and the other 3 residues have discrepancies between solution and crystals. I16 has a single conformation in multiple SpA-domain crystal structures, whereas its χ 2 angle appears to be dynamic, with predicted gauche-and trans populations of 0.2 and 0.8, respectively (25) . Likewise, L45 has a single conformation in crystal structures but has a dynamic χ 2 angle, with trans and gauche+ populations of 0.43 and 0.57, respectively (26) . Apparently crystallization reduces the dynamics in these two residues. Finally, T23 appears to be dynamic by NMR but has only one conformer in crystals. This side chain forms a crystal contact in the SpA C structure, which may freeze out its dynamics. The general agreement between NMRdetected side-chain dynamics of SpA C in solution and the rotameric heterogeneity observed in crystals lends further support to our observation that rotameric heterogeneity is greatly reduced from SpA C in the apo state to form the SpA C -F c complex. Such a reduction in heterogeneity is similar to that observed in the multifunctional proteins ubiquitin (27) and calmodulin (28) . Although the new structure includes the same helix 1/2 SpA C interface from the 1FC2 structure, two SpA C molecules also bind to the F c dimer on their helix 2/3 interfaces (Fig. S2) . On the F c side of this previously unidentified binding interface, the orientation of the IgG fold relative to SpA C differs greatly from that of F ab in the 1DEE F ab -SpA D complex (10) . The SpA D is bound to the VH domain of F ab , whereas the SpA C at the previously unidentified interface interacts with the hinge region of F c (Fig. S2A) . However, whereas the binding modes for the IgG fragments are quite different, the interfaces on the SpA-domain side are homologous. Both F ab and F c bind at the helix 2/3 interface of SpA. The majority of SpA C residues involved in binding F c at this interface are the same as the SpA D residues that bind to F ab . These residues adopt very similar rotamer conformations in both complex structures (Fig. S2B) . Previous isothermal titration calorimetry (ITC) studies indicated that F c binds to full-length SpA with a stoichiometry of 2.35 ± 0.32 (8) . However, because SpA contains five individual protein-binding domains that each may bind to multiple proteins simultaneously, it is difficult to tease apart the stoichiometry for individual domains. Therefore, we measured the binding stoichiometry at 5 μM via ITC by titrating F c into SpA C (Fig. S3A ) and SpA C into F c (Fig. S3B) . Both binding isotherms were simultaneously fit to obtain a stoichiometric ratio of ∼1.1 (Fig.  S3C) . However, the K D cannot be accurately estimated, because the c value (29) is much greater than 100 at 5 μM. We estimate that the K D is at least 10 nM or tighter, which is consistent with previous estimates (8) .
To determine the minimal affinity detectable by our ITC experiments, we simulated two-site isotherms using the best-fit K D value for the tight site and various K d values for the second binding site (Fig. S3D) . The second binding site was only apparent in the simulated isotherms if the second-site K D was 10 μM or tighter. The concentration of F c in our crystallization conditions was 100-200 μM. On this basis, we conclude that the second-site K D must be in this range and, therefore, the interface we observe in our crystals between SpA C helix 2/3 and F c is a low-affinity interaction that would occur only at high local concentrations of both proteins. It may be that such high local concentrations could occur when antibodies are bound at the S. aureus cell surface, which could make the helix 2/3-binding site functionally relevant.
SpA Contains an Important Molecular-Recognition Pocket for F c .
A detailed analysis of the atomic interactions between SpA domains and F c provides key insights into the binding reaction and its structural determinants. The improved resolution of our F c -SpA domain complex structure allows us to visualize previously unidentified side-chain interactions. In particular, F5 undergoes a large rotamer change (Fig. 4A ). In the apo structure (orange sticks), the aromatic ring nestles into a pocket between Q9 of helix 1 (green sticks) and the C-terminal end of helix 2. The placement of the ring is supported by NOEs observed in the solution structure on another SpA domain between F5 and nearby residues [BioMagResBank (BMRB) accession no. 4023 (30) ], depicted as dashes. However, in the complex structure, F5 flips outward to accommodate F c I253, which makes van der Waals interactions with the same pocket. F5 docking and displacement are facilitated by the flexibility of its backbone. We hypothesized that substitution of nearby Q9 with a bulky tryptophan might prefill the pocket and lower the affinity of F c for SpA.
To test this hypothesis, we solved the crystal structure of apo SpA C Q9W (Table S4) , which contains two chains of SpA C Q9W in the asymmetric unit. To avoid confusion with the wild-type structure, all residues from SpA C Q9W are labeled with an asterisk (*). Just as I253 displaces F5 in the wild-type complex, W9* displaces F5* in both chain A (green sticks in Fig. 4B ) and chain B of the Q9W variant, causing the F5* side chain and backbone to flip outward. The W9* indole ring adopts a favorable rotamer (50% rotamericity) and fills the pocket in a way that would sterically block F c I253 from binding. Just as in wildtype SpA C , we measured the affinity constant K D and the binding stoichiometry at 5 μM via ITC by titrating SpA C Q9W into F c (Fig. 4C) . The binding isotherm was fit to obtain an n value of 1.0 ± 0.006 and a K D of 170 ± 3 nM (c, 29), which is 17-fold weaker than the maximum value we estimated for the K D of wild-type SpA C (see above). To understand the structural basis for this reduction in affinity, we solved the crystal structure of SpA C Q9W in complex with F c (Fig. 4B and Table S5 ). I253 in the Q9W complex binds to the same pocket as it does in wild-type SpA C and adopts the same rotamer. However, binding of I253 to the F5 pocket requires the W9* side chain to flip outward and adopt a less-favorable rotamer (12% rotamericity). This observation suggests that a small-molecule drug bound to this pocket would hinder I253 binding in a similar way, thereby significantly reducing the affinity for antibody. Such a small molecule could serve as both a novel therapeutic for combating S. aureus infection and as an important biotechnology tool for purifying antibodies by allowing displacement of antibodies from SpA columns at higher pH.
The helix 1/2 interface on SpA domains can bind many proteins, including the F c fragment of IgG (9), TNF-α receptor 1 (5), von Willebrand factor (6) , and the C1qR component of complement (31) . We previously reported the enhanced conformational heterogeneity at the helix 1/2 interface of SpA C , which may help SpA accommodate multiple binding partners (16) .
The enhanced heterogeneity at the helix 1/2 interface and throughout the protein suggests that binding is coupled to rotameric conformational changes, which presumably are required for binding of other partner proteins, such as TNFR1 and vWf, to this interface. The virulence conferred by SpA is a direct result of its ability to bind many protein partners. SpA domains could possibly bind multiple antibodies simultaneously, F c at the heterogeneous helix 1/2 interface and F ab at the helix 2/3 interface. It is also possible that the second binding site we observed in our structure may play a role in polyvalent antibody binding when primary-site binding raises the effective concentrations of both proteins. This polyvalent binding strategy is frequently observed at cell surfaces, and may play a key role in the ability of S. aureus to evade the host immune system.
Future studies of this system will seek to confirm and further quantitate the binding-induced loss in conformational heterogeneity on a residue-by-residue basis. If the loss of conformational heterogeneity we detect in the R ρ analysis (Table S2) is confirmed by other methods, this observation would suggest that the binding affinity of SpA C for Fc is reduced by the entropic penalty associated with the suppression of conformational heterogeneity upon binding. It is easy to imagine ways that the evolved SpA sequence might have compensated for this entropic penalty. We previously hypothesized that the large extent of conformational heterogeneity in SpA domains might potentiate their binding promiscuity (16) . Formally, this plasticity would come at an entropic cost to affinity to any one partner, but presumably allows S. aureus to use one surface protein to exquisitely enhance its virulence via multiple mechanisms of infection.
Experimental Procedures
Plasmid Construction. The SpA C gene was PCR-cloned from the SpA-N gene. The PCR primers added 5′ NdeI and 3′ BamHI sites, and were subsequently cloned into the T7 expression plasmid pAED4 (32) . The SpA c Q9W plasmid was formed through site-directed mutagenesis of the wild-type SpA C plasmid. The F c gene of IgG was amplified from pEFc31 (18) . The PCR primers added 5′ NcoI and 3′ Xhol sites that were used to subclone the F c gene into pET28a (Novagen).
Protein Expression and Purification. SpA C proteins. SpA C plasmids were transformed into Escherichia coli BL21(DE3) cells using a standard transformation procedure. A single colony of transformed bacteria was used to inoculate a 50-mL culture of Luria broth media with 0.1 mg/mL ampicillin. This starter culture was incubated at 37°C until the optical density (OD) reached 0.8, whereupon it was used to inoculate a 1-L culture that was allowed to grow to OD 0.8 at 37°C. Isopropylbeta-D-thiogalactopyranoside (IPTG) was then added to a final concentration of 1 mM, and the culture was incubated for an additional 6-8 h. The cells were harvested by centrifugation at 6,700 × g and resuspended in 20-30 mL of 50 mM Tris (pH 8.8), 1 mM EDTA. The cells were lysed in a French pressure cell, and insoluble material was centrifuged from the lysate at 25,000 × g. The lysate was brought to pH 9.0, and micrococcal nuclease was added to digest large DNA fragments for 15 min. The resulting solution was brought to 4 M guanidinium HCl (Bio Basic). The solution was then dialyzed in a 5% (vol/vol) acetic acid buffer in two successive steps, which precipitated many cellular materials but not expressed SpA C . After centrifugation of the insoluble material at 25,000 × g, the resulting solution was allowed to dialyze overnight into deionized water. SpA C was further purified using a strong cation-exchanging SP Sepharose (GE Healthcare) column in 50 mM acetate buffer at pH 3.6. Protein was eluted with an NaCl gradient of typically 100-500 mM in a volume of 600-800 mL and collected in 10-mL fractions monitored by a UV detector (Bio-Rad) at 278 nm. Fractions comprising the protein elution peak were checked for purity by SDS/PAGE. The purest fractions were pooled and dialyzed against deionized water. The final solution was lyophilized and stored in a desiccator. The purity of the final protein stock was confirmed by SDS/PAGE to be >95% pure. The mass of SpA C was confirmed with electrospray ionization mass spectroscopy. F c protein. The F c plasmid was transformed into E. coli Rosetta-gami 2 B competent cells (EMD Millipore) using a standard transformation procedure. A single colony of transformed bacteria was used to inoculate a 5-mL culture of Luria broth media with ampicillin (100 μg/mL), chloramphenicol (35 μg/mL), and kanamycin (50 μg/mL). This starter culture was incubated at 37°C for 24 h, whereupon 1 mL of this culture was used to inoculate a 200-mL culture. After 24 h of growth, the entirety of this culture was used to inoculate a 700-mL culture. IPTG was immediately added to a final concentration of 1 mM, and the culture was incubated for an additional 24 h. The cells were harvested by centrifugation at 6,700 × g and resuspended in 20 mL of 20 mM Tris (pH 8), 300 mM NaCl, 20% glycerol. The cells were lysed in a Microfluidizer (Microfluidics), and insoluble material was centrifuged from the lysate at 25,000 × g. The lysate was loaded on an Ni-NTA affinity column, washed with 20 mM Tris (pH 8), 500 mM NaCl, 20 mM imidazole, 20% glycerol, and eluted with 20 mM Tris pH (8) , 100 mM NaCl, 200 mM imidazole in 5-mL fractions. The fractions comprising the protein elution peak were checked for purity by SDS/PAGE. The purest fractions were pooled and further purified using a Sephadex 200 size-exclusion column and eluted using 200 mL of 20 mM Hepes (pH 8), 50 mM NaCl in 1-mL fractions monitored by a UV detector at 280 nm. Peak fractions were checked for purity by SDS/PAGE. The purest fractions were pooled and concentrated.
Crystallization, Data Collection, Modeling, and Refinement. F c and SpA C proteins were mixed in a 2:1 molar ratio for 1 h at a concentration of 10 mg/mL complex. Each complex was mixed in a 1:2 ratio with crystallization solution (0.1 M NaOAc, pH 5.6, 0.1 M ammonium sulfate, 15% PEG 5K MME). Crystals of both complexes formed by sitting-drop vapor diffusion within 5 d at room temperature, and were of the space group C2. The SpA c Q9W variant was mixed in a 1:1 molar ratio with crystallization solution (10 mM NaSCN, 18% PEG 3350). Crystals were each frozen by direct immersion in liquid nitrogen after addition of ethylene glycol to 20% (vol/vol). All data were collected remotely at the Advanced Photon Source (APS) at Argonne National Laboratory, beamline 22-ID (Southeast Regional Collaborative Access Team) at 100 K. Data were processed and scaled to 2.3-Å resolution with HKL2000 (33) . Both structures of SpA C in complex with F c were solved using molecular replacement in Phaser (34) using PDB ID codes 4NPD (35) and 1FC2 (11) . The SpA c Q9W variant was solved using molecular replacement in Phaser using PDB ID code 4NPD (helices 2 and 3 only). All models were built in Coot (36) . Refinement of all models was carried out in phenix.refine (20) . Refinement was performed using isotropic B factors for all atoms. Alternative conformations were modeled using qFit (24 C heteronuclear single quantum coherence experiment (22, 23) . The reference and J-modulated spectra were recorded in an interleaved manner with a constant-time delay (2T) set to 57.4 ms to refocus the 1 J CC coupling. The maximum evolution times for the 13 C and 1 H dimensions were 18.1 and 60 ms, respectively. The spectra were processed with NMRPipe (37) using the sine-bell window function for both dimensions, and the indirect dimension was zero-filled fourfold before Fourier transform. The peak intensities were measured by SPARKY (38) , and the 3 J(Cγ,C′) and 3 J(Cγ,N) couplings were calculated from the ratio of the peak intensities between the J-modulated spectrum (I mod ) and the reference spectrum for the Ile residues were measured on an Agilent 800-MHz NMR spectrometer at 25°C using the long-range 13 C-13 C correlation experiment reported previously (21) with minor modifications. The CO 180 refocused pulses during the two 2T periods were removed, and the CO composite pulse decouple was introduced during the t 1 evolution to remove 1 J(Cα,CO) coupling. The constant-time delay was set to 29.4 ms to refocus 1 J cc couplings. The maximum evolution times were 4 and 80 ms for the 13 C and 1 H dimensions, respectively. Both dimensions were processed using the sine-bell window function, and the indirect dimension was zero-filled 16-fold before Fourier transform. All data were processed by NMRPipe (37), and peak volumes were obtained by automatic integration using the peakint module in the XEASY package (39 Illustrations. All structural illustrations were made in PyMOL (Schrödinger, LLC). It is difficult to quantitatively estimate the uncertainty in electron-density values; therefore, we have not included uncertainties in R ρ . Qualitatively, sources of error that contribute to uncertainty in electron density and therefore R ρ include data collection errors, crystal defects, modeling errors, and refinement artifacts. *Interfacial residues.
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† Numbers in parentheses are SDs. ‡ Based on a Student t hypothesis test. The P value is the probability that interfacial and noninterfacial residues have the same reductions in conformational heterogeneity upon F c binding. 
